N4 Pharma PLC Holding(s) in Company (8771I)
13 Agosto 2019 - 05:16AM
UK Regulatory
TIDMN4P
RNS Number : 8771I
N4 Pharma PLC
13 August 2019
13 August 2019
N4 Pharma Plc
("N4 Pharma" or the "Company")
Holdings in Company
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for vaccines and
cancer treatments, announces that it has been notified that,
following a purchase of 112,258 ordinary shares of 0.4p each in the
company ("Ordinary Shares") earlier today, Mr David Farrier is now
beneficially interested in 12,175,510 Ordinary Shares, representing
12.0 per cent. of the Company's issued share capital.
Enquiries:
N4 Pharma Plc Via Scott PR
Nigel Theobald, CEO
Allenby Capital Limited Tel: +44(0)203 328 5656
James Reeve/Asha Chotai
Scott PR Tel: +44(0)1477 539 539
Georgia Smith
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for vaccines and cancer treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for vaccines and cancer treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
HOLLLFLITSIVLIA
(END) Dow Jones Newswires
August 13, 2019 06:16 ET (10:16 GMT)
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024